Jefferies Financial Group Inc. Boosts Stock Holdings in Medpace Holdings, Inc. $MEDP

Jefferies Financial Group Inc. increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 30.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,713 shares of the company’s stock after purchasing an additional 2,481 shares during the period. Jefferies Financial Group Inc.’s holdings in Medpace were worth $6,017,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Optiver Holding B.V. purchased a new position in Medpace during the third quarter worth about $27,000. Steigerwald Gordon & Koch Inc. purchased a new position in Medpace during the fourth quarter worth about $30,000. Elyxium Wealth LLC purchased a new position in Medpace during the fourth quarter worth about $30,000. Quarry LP purchased a new position in Medpace during the third quarter worth about $35,000. Finally, Root Financial Partners LLC purchased a new position in Medpace during the third quarter worth about $38,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 20.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a research report on Friday, February 13th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Truist Financial lowered their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Royal Bank Of Canada lowered their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Finally, BMO Capital Markets lowered their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Medpace presently has a consensus rating of “Hold” and an average price target of $467.08.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $432.80 on Tuesday. Medpace Holdings, Inc. has a 1 year low of $287.17 and a 1 year high of $628.92. The firm’s 50 day moving average price is $458.70 and its 200 day moving average price is $517.79. The firm has a market cap of $12.36 billion, a P/E ratio of 27.20, a price-to-earnings-growth ratio of 2.20 and a beta of 1.19.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. Medpace’s revenue was up 26.5% on a year-over-year basis. During the same quarter last year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.